Evidence map›Paper›PMID 39190360›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

HIV-1 control in vivo is related to the number but not the fraction of infected cells with viral unspliced RNA.

Adam A Capoferri, Ann Wiegand, Feiyu Hong, Jana L Jacobs, Jonathan Spindler, Andrew Musick, Michael J Bale, Wei Shao, Michele D Sobolewski, Anthony R Cillo and 9 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. The elite controller phenotype.Current opinion in HIV and AIDS · 2026
    Review
  4. Article
  5. Article
  6. HIV-1 control in vivo is related to the number but not the fraction of infected cells with viral unspliced RNA.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Adam A CapoferriHIV Dynamics and Replication Program, National Cancer Institute, Frederick, MD 21702.ORCID 0000-0002-6048-2115
Ann WiegandHIV Dynamics and Replication Program, National Cancer Institute, Frederick, MD 21702.
Feiyu HongDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.
Jana L JacobsDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.
Jonathan SpindlerHIV Dynamics and Replication Program, National Cancer Institute, Frederick, MD 21702.
Andrew MusickLeidos Biomedical Research, Inc., Frederick National Laboratories for Cancer Research, Frederick, MD 21702.
Michael J BaleHIV Dynamics and Replication Program, National Cancer Institute, Frederick, MD 21702.
Wei ShaoLeidos Biomedical Research, Inc., Frederick National Laboratories for Cancer Research, Frederick, MD 21702.
Michele D SobolewskiDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.
Anthony R CilloDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261.
Brian T LukeLeidos Biomedical Research, Inc., Frederick National Laboratories for Cancer Research, Frederick, MD 21702.
Christine M FennesseyAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
Robert J GorelickAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
Rebecca HohDepartment of Medicine, University of California, San Francisco, CA 94143.
Elias K HalvasDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.
Steven G DeeksDepartment of Medicine, University of California, San Francisco, CA 94143.
John M CoffinDepartment of Molecular Biology and Microbiology, Tufts University, Boston, MA 02111.
John W MellorsDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.
Mary F KearneyHIV Dynamics and Replication Program, National Cancer Institute, Frederick, MD 21702.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Human endogenous provirus inhibition of HIV replicationR01AI184043 · NIAID · TUFTS UNIVERSITY BOSTON · PI JOHN M COFFIN · 2024 to 2026
$2.1M
HHS | NIH | NIAID | Division of Intramural Research (DIR, NIAID) 1 R01 AI 184043-01Leidos Biomedical 12XS547Leidos Biomedical 13SX110NCI NIH HHS 75N91019D00024NCI NIH HHS CA R35 200421NCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INCI NIH HHS IntramuralNIAID NIH HHS R01 AI184043NIH HHS HHSN261201500003I
6 · The paper itself

Abstract

In the absence of antiretroviral therapy (ART), a subset of individuals, termed HIV controllers, have levels of plasma viremia that are orders of magnitude lower than non-controllers (NC) who are at higher risk for HIV disease progression. In addition to having fewer infected cells resulting in fewer cells with HIV RNA, it is possible that lower levels of plasma viremia in controllers are due to a lower fraction of the infected cells having HIV-1 unspliced RNA (HIV usRNA) compared with NC. To directly test this possibility, we used sensitive and quantitative single-cell sequencing methods to compare the fraction of infected cells that contain one or more copies of HIV usRNA in peripheral blood mononuclear cells (PBMC) obtained from controllers and NC. The fraction of infected cells containing HIV usRNA did not differ between the two groups. Rather, the levels of viremia were strongly associated with the total number of infected cells that had HIV usRNA, as reported by others, with controllers having 34-fold fewer infected cells per million PBMC. These results reveal that viremic control is not associated with a lower fraction of proviruses expressing HIV usRNA, unlike what is reported for elite controllers, but is only related to having fewer infected cells overall, maybe reflecting greater immune clearance of infected cells. Our findings show that proviral silencing is not a key mechanism for viremic control and will help to refine strategies toward achieving HIV remission without ART.

Indexed as

HIV-1HIV InfectionsLeukocytes, MononuclearRNA, ViralViremiaAdultFemaleHumansMaleMiddle AgedViral LoadRNA, ViralCARD-SGSHIV controllersHIV latencyHIV proviral expressionHIV RNA

Identifiers

PMID39190360
PMCPMC11388345

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.